A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018)

Patnaik Amita; Gordon Michael; Tsai Frank; Papadopoulos Kyriakos P.; Rasco Drew; Beeram Muralidhar; Fu Siqing; Janku Filip; Hynes Scott M.; Gundala Sushma R.; Willard Melinda D.; Zhang Wei; Lin Aimee Bence; Hong David

首页> 外文期刊>Cancer chemotherapy and pharmacology. >A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018)

【24h】

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018)

机译：I阶段I的Ly3164530研究，靶向患者和转移性癌症患者（Vol 82，PG 407,2018）的靶向患者和EGFR的双特异性抗体研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The original version of this article unfortunately contained a mistake. The co-authors' names were incorrect.

机译：不幸的是，这篇文章的原始版本包含了一个错误。合著者的名字不正确。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2018年第3期|共1页
作者
Patnaik Amita; Gordon Michael; Tsai Frank; Papadopoulos Kyriakos P.; Rasco Drew; Beeram Muralidhar; Fu Siqing; Janku Filip; Hynes Scott M.; Gundala Sushma R.; Willard Melinda D.; Zhang Wei; Lin Aimee Bence; Hong David;
展开▼
作者单位

START 4383 Med Dr Suite 4026 San Antonio TX 78229 USA;

HonorHlth Res Inst Scottsdale AZ USA;

HonorHlth Res Inst Scottsdale AZ USA;

START 4383 Med Dr Suite 4026 San Antonio TX 78229 USA;

START 4383 Med Dr Suite 4026 San Antonio TX 78229 USA;

START 4383 Med Dr Suite 4026 San Antonio TX 78229 USA;

Univ Texas MD Anderson Canc Ctr Canc Med Div Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Canc Med Div Houston TX 77030 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Univ Texas MD Anderson Canc Ctr Canc Med Div Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase Ⅰ dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer [J] . Yihebali Chi, Jianliang Yang, Sheng Yang, 中国癌症研究（英文版） . 2015,第003期
2. Study on the influence of NC for the serum MMP, VEGF and PG of patients with advanced gastric cancer [J] . Guang-Mang Lai, Hong-Wei Huang, Zhi-Wei Chen, 海南医科大学学报（英文版） . 2016,第004期
3. Final Overall Survival Results from the FLAURA Trial: a Phase Ⅲ Study on Osimertinib in EGFR-Mutated Advanced Non-small Cell Lung Cancer [J] . Yue WANG, Juan NAN 国际转化医学杂志（英文版） . 2020,第002期
4. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018) [J] . Patnaik Amita, Gordon Michael, Tsai Frank, Cancer chemotherapy and pharmacology. . 2018,第3期

机译：患有先进或转移性癌症的患者（Vol 82，PG 407,2018）的患者靶向患者和EGFR的双特异性抗体，靶向抗体，靶向患者和EGFR的阶段研究
5. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer [J] . Patnaik Amita, Gordon Michael, Tsai Frank, Cancer chemotherapy and pharmacology. . 2018,第3期

机译：I阶段研究Ly3164530，靶向患者和转移性癌症患者的双特异性抗体，靶向患者和EGFR
6. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors (vol 36, pg 3298, 2018) [J] . Strickler J. H., Weekes C. D., Nemunaitis J. Journal of Clinical Oncology . 2019,第3期

机译：患有先进实体瘤的患者的靶向C-MET的抗体 - 药物缀合物的抗体 - 药物缀合物的抗体 - 药物缀合物的第一阶段I，剂量 - 升级和延伸研究（Vol 36，PG 3298,2018）
7. The Benefits of Bispecific mAb-square Antibodies Targeting EGFR and HGF [C] . Melanie Medcalf, Kin-Mei Leung, Samine Isaac, Protein Engineering Summit. . 2018

机译：靶向EGFR和HGF的双特异性mAB-方抗体的益处
8. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
9. A phase I study of LY3164530 a bispecific antibody targeting MET and EGFR in patients with advanced or metastatic cancer [O] . Amita Patnaik, Michael Gordon, Frank Tsai, -1

机译：一项针对MET和EGFR的双特异性抗体LY3164530在患有晚期或转移性癌症的患者中进行的I期研究
10. Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS) [O] . 2015

机译：五名晚期胰腺癌患者在抗CD3 x抗EGFR双特异性抗体武装的活化T细胞（BATS）的I期研究中
11. Cell Penetrating Bispecific Antibodies for Targeting Oncogenic Transcription Factors in Advanced Prostate Cancer. [R] . Lilly, M., Weisbart, R. 2016

机译：细胞穿透双特异性抗体靶向晚期前列腺癌的致癌转录因子。

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018)

摘要

著录项

相似文献

相关主题

期刊订阅